Citations

Mayo Clinic

Showing 10 of 108523 citations.

Steganalysis of Medical Radiographs for Radiographic Machine Identification
Mohammadi, Farid Ghareh , Sebro, Ronnie

2023 International Conference on Computational Science and Computational Intelligence (CSCI) | July 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1189-1196

10.1109/csci62032.2023.00194 Get It

DeepCT-SI: Deep Learning Algorithm for Computed Tomography Source Identification
Mohammadi, Farid Ghareh , Sebro, Ronnie

2023 International Conference on Computational Science and Computational Intelligence (CSCI) | July 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1117-1124

10.1109/csci62032.2023.00184 Get It

Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death
Corley, Douglas A. , Levin, Theodore R. , Ghai, Nirupa R. , Zhao, Wei , Buckner‐Petty, Skye , Fletcher, Robert H., Schottinger, Joanne E. , Buckner-Petty, Skye, Doubeni, Chyke A. , Jensen, Christopher D. , Cannavale, Kimberly L. , Selby, Kevin , Zauber, Ann Graham , Weiss, Noel S

JAMA Network Open | July 19, 2024 | Volume: 7 | Issue: 7 | Pages: e2423671

10.1001/jamanetworkopen.2024.23671 | PMID 39028667 Get It

ImportanceThe fecal immunochemical test (FIT) is widely used for colorectal cancer (CRC) screening, but evidence of its effectiveness is limited.ObjectiveTo evaluate whether FIT screening is associated with a lower risk of dying from CRC overall, according to cancer location, and within demographic groups.Design, Setting, and ParticipantsThis nested case-control study in a cohort of screening-eligible people was conducted in 2 large, integrated health systems of racially, ethnically, and socioeconomically diverse members with long-term programs of mailed FIT screening outreach. Eligible participants included people aged 52 to 85 years who died from colorectal adenocarcinoma between 2011 and 2017 (cases); cases were matched in a 1:8 ratio based on age, sex, health-plan membership duration, and geographic area to randomly selected persons who were alive and CRC-free on case’s diagnosis date (controls). Data analysis was conducted from January 2002 to December 2017.ExposuresCompleting 1 or more FIT screenings in the 5-year period prior to the CRC diagnosis date among cases or the corresponding date among controls; in secondary analyses, 2- to 10-year intervals were evaluated.Main Outcomes and MeasuresThe primary study outcome was CRC death overall and by tumor location. Secondary analyses were performed to assess CRC death by race and ethnicity.ResultsFrom a cohort of 2 127 128 people, a total of 10 711 participants (3529 aged 60-69 years [32.9%]; 5587 male [52.1%] and 5124 female [47.8%]; 1254 non-Hispanic Asian [11.7%]; 973 non-Hispanic Black [9.1%]; 1929 Hispanic or Latino [18.0%]; 6345 non-Hispanic White [59.2%]) was identified, including 1103 cases and 9608 controls. Among controls during the 10-year period prior to the reference date, 6101 (63.5%) completed 1 or more FITs with a cumulative 12.6% positivity rate (768 controls), of whom 610 (79.4%) had a colonoscopy within 1 year. During the 5-year period, 494 cases (44.8%) and 5345 controls (55.6%) completed 1 or more FITs. In regression analysis, completing 1 or more FIT screening was associated with a 33% lower risk of death from CRC (adjusted odds ratio [aOR], 0.67; 95% CI, 0.59-0.76) and 42% lower risk in the left colon and rectum (aOR, 0.58; 95% CI, 0.48-0.71). There was no association with right colon cancers (aOR, 0.83; 95% CI, 0.69-1.01) but the difference in the estimates between the right colon and left colon or rectum was statistically significant (P = .01). FIT screening was associated with lower CRC mortality risk among non-Hispanic Asian (aOR, 0.37; 95% CI, 0.23-0.59), non-Hispanic Black (aOR, 0.58; 95% CI, 0.39-0.85) and non-Hispanic White individuals (aOR, 0.70; 95% CI, 0.57-0.86) (P for homogeneity = .04 for homogeneity).Conclusions and RelevanceIn this nested case-control study, completing FIT was associated with a lower risk of overall death from CRC, particularly in the left colon, and the associations were observed across racial and ethnic groups. These findings support the use of FIT in population-based screening strategies.
Treatment options for necrotizing scleritis in rheumatoid arthritis patients
Kraker, Jessica A. , Smith, Wendy M.

Expert Review of Ophthalmology | July 19, 2024 | Volume: 19 | Issue: 5 | Pages: 357-377

10.1080/17469899.2024.2382148 Get It

Health & Wellness Coaching Services: Making the Case for Reimbursement
Reddy, Kavitha P. , Beech, Bettina M. , Moore, Margaret , Abu Dabrh, Abd Moain , Moore, Margaret , Dabrh, Abd Moain Abu

American Journal of Lifestyle Medicine | July 19, 2024 | Volume: 19 | Issue: 6 | Pages: 800-813

10.1177/15598276241266784 | PMID 39554945 Get It

In 2020, a consortium composed of three national coach credentialing organizations, four medical societies, and 72 healthcare organizations led by National Board for Health and Wellness Coaching (NBHWC) was formed to advocate for the reimbursement of Health and Wellness Coaching (HWC) services in the U.S. healthcare system. Building on that, the NBHWC and the Veterans Health Administration (VHA) initiated a pivotal collaboration in 2023, with a target audience comprised influential reimbursement policymakers, notably the American Medical Association’s Current Procedural Terminology (CPT®) Panel and the Centers for Medicare & Medicaid Services (CMS). This concerted effort led to CMS announcing the temporary inclusion of HWC services on the 2024 Medicare Telehealth list. This ongoing advocacy work is crucial while understanding its key components is imperative for wider participation. This paper aims to distill the essence of the advocacy to date into a coherent narrative. By doing so, we seek to share with stakeholders—health and wellness coaches, medical professionals, healthcare organizations, patient advocates, and policy experts—a robust framework to support advocacy for reimbursement to both government and private insurers, at local and national levels. This initiative marks a significant milestone in healthcare policy, reflecting a growing recognition and impact of HWC.
Association Between Surgeon Sex and Days Alive at Home Following Surgery: A Population-Based Cohort Study
Heybati, Kiyan , Satkunasivam, Raj , Aminoltejari, Khatereh, Thomas, Hannah S. , Salles, Arghavan , Coburn, Natalie, Wright, Frances C. , Conn, Lesley Gotlib , Riveros, Carlos , McCartney, Colin J. L. , Armstrong, Kathleen , Bass, Barbara L. , Detsky, Allan S. , Coburn, Natalie, Luckenbaugh, Amy N. , Ranganathan, Sanjana , Jerath, Angela , Wallis, Christopher J D

Annals of Surgery Open | July 19, 2024 | Volume: 5 | Issue: 3 | Pages: e477

10.1097/as9.0000000000000477 | PMID 39310349 Get It

Objective: The objective of this study was to measure potential associations between surgeon sex and number of days alive and at home (DAH). Background: Patients treated by female surgeons appear to have lower rates of mortality, complications, readmissions, and healthcare costs when compared with male surgeons. DAH is a validated measure, shown to better capture the patient experience of postoperative recovery. Methods: We conducted a retrospective study of adults (≥18 years of age) undergoing common surgeries between January 01, 2007 and December 31, 2019 in Ontario, Canada. The outcome measures were the number of DAH within 30-, 90-, and 365-days. The data was summarized using descriptive statistics and adjusted using multivariable generalized estimating equations. Results: During the study period, 1,165,711 individuals were included, of which 61.9% (N = 721,575) were female. Those managed by a female surgeon experienced a higher mean number of DAH when compared with male surgeons at 365 days (351.7 vs. 342.1 days; P < 0.001) and at each earlier time point. This remained consistent following adjustment for covariates, with patients of female surgeons experiencing a higher number of DAH at all time points, including at 365 days (343.2 [339.5–347.1] vs. 339.4 [335.9–343.0] days). Multivariable regression modeling revealed that patients of male surgeons had a significantly lower number of DAH versus female surgeons. Conclusions: Patients of female surgeons experienced a higher number of DAH when compared with those treated by male surgeons at all time points. More time spent at home after surgery may in turn lower costs of care, resource utilization, and potentially improve quality of life. Further studies are needed to examine these findings across other care contexts.
Studying the Association of Enterococcal and Gram-Negative Pathogens with Longitudinal Spread of Antibiotic Resistance Among Anesthesia Workspace Reservoirs on Future Surgical Dates
Hwang, Soyun M, Dexter, Franklin , Parra, Michelle C. , Loftus, Randy W. , Hwang, Soyun Michelle, Charnin, Jonathan E.

Anesthesia & Analgesia | July 19, 2024 | Volume: 139 | Issue: 6 | Pages: 1349-1351

10.1213/ane.0000000000007129 | PMID 39028657 Get It

Deformable dose accumulation is required for adaptive radiotherapy practice
Zhong, Hualiang , Pursley, J. , Rong, Yi

Journal of Applied Clinical Medical Physics | July 19, 2024 | Volume: 25 | Issue: 8 | Pages: No page available

10.1002/acm2.14457 | PMID 39031438 Get It

Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference
Kloske, Courtney M. , Blue, Elizabeth , Carrillo, María C. , Chen, Xiaoying , Chiba‐Falek, Ornit , Davis, Albert A. , Paolo, Gilbert Di , Garretti, Francesca , Golden, Lesley R. , Heinecke, Jay W. , Herz, Joachim, Huang, Yadong , Kanekiyo, Takahisa , Khvorova, Anastasia, Hertog, Sascha J. Koppes‐den, Lamb, Bruce T. , Lawler, Paige E. , Litvinchuk, Alexandra , Liu, Chia‐Chen , Michaelson, D. M., Miller, Justin J. , Morganti, Josh M. , Oosthoek, Marlies , Ramachandran, Kapil V. , Ramakrishnan, Abhirami , Robert, Aiko, Sexton, Claire E. , Shah, Nilomi, Shue, Francis , Strickland, Michael R. , TCW, Julia , Thierry, Manon, Tuckey, Ryan A. , Ulrich, Jason D. , Wang, Na , Weninger, Stacie, Zhao, Na , Goate, Alison , Liu, Chia-Chen , Shue, Francis , Zhao, Na , Goate, Alison M , Belloy, Michaël E. , Bowman, Gregory R. , Gate, David M , Iadecola, Costantino , Johnson, Lance A. , Karch, Celeste M. , Khvorova, Anastasia , Hertog, Sascha Koppes-den , Le Guen, Yann , Mahinrad, Simin , Marcora, Edoardo , Mariño, Claudia , Narayan, Priyanka , Naslavsky, Michel Satya , Raulin, Ana‐Caroline , Saleh, Rasha N.M. , Sible, Isabel J. , Soranno, Andrea , Tsai, Li‐Huei , Kant, Rik van der , Wellington, Cheryl L. , Yassine, Hussein N. , Bu, Guojun , Holtzman, David M.

Alzheimer's & Dementia | July 19, 2024 | Volume: 20 | Issue: 9 | Pages: 6590-6605

10.1002/alz.13877 | PMID 39031528 Get It

AbstractINTRODUCTIONThe apolipoprotein E gene (APOE) is an established central player in the pathogenesis of Alzheimer's disease (AD), with distinct apoE isoforms exerting diverse effects. apoE influences not only amyloid‐beta and tau pathologies but also lipid and energy metabolism, neuroinflammation, cerebral vascular health, and sex‐dependent disease manifestations. Furthermore, ancestral background may significantly impact the link between APOE and AD, underscoring the need for more inclusive research.METHODSIn 2023, the Alzheimer's Association convened multidisciplinary researchers at the “AAIC Advancements: APOE” conference to discuss various topics, including apoE isoforms and their roles in AD pathogenesis, progress in apoE‐targeted therapeutic strategies, updates on disease models and interventions that modulate apoE expression and function.RESULTSThis manuscript presents highlights from the conference and provides an overview of opportunities for further research in the field.DISCUSSIONUnderstanding apoE's multifaceted roles in AD pathogenesis will help develop targeted interventions for AD and advance the field of AD precision medicine.Highlights APOE is a central player in the pathogenesis of Alzheimer's disease. APOE exerts a numerous effects throughout the brain on amyloid‐beta, tau, and other pathways. The AAIC Advancements: APOE conference encouraged discussions and collaborations on understanding the role of APOE.
Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights
Mangioris, Georgios , Pittock, Sean J. , Yang, Binxia , Fryer, James P., Harmsen, William S. , Dubey, Divyanshu , López‐Chiriboga, A. Sebastian , McKeon, Andrew , Mills, John R. , Vodopivec, Ivana, Toledano, Michel , Aksamit, Allen J. , Ζεκερίδου, Αναστασία , Pittock, S J , Flanagan, E P , Lopez-Chiriboga, A Sebastian , McKeon, Andrew , Tobin, W Oliver , Toledano, Michel , Zekeridou, Anastasia , Dubey, Divyanshu , Yang, Binxia , Flanagan, Eoin P. , Tobin, W. Oliver

Annals of Neurology | July 19, 2024 | Volume: 96 | Issue: 4 | Pages: 704-714

10.1002/ana.27024 | PMID 39031103 Get It

ObjectiveTo evaluate the cerebrospinal fluid (CSF) cytokine/chemokine profile of central nervous system (CNS) neurosarcoidosis (NS), and its utility in differential diagnosis, treatment, and prognostication.MethodsIn this case–control study, we validated 17 cytokines/chemokines (interleukin [IL]‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐10, IL‐12p70, IL‐13, IL‐17A, BAFF, IL‐8/CXCL8, CXCL9, CXCL10, CXCL13, GM‐CSF, interferon‐gamma, and tumor necrosis factor [TNF]‐alpha) in a multiplexed automated immunoassay system (ELLA; Bio‐Techne, Minneapolis, MN, USA), and assessed them in CSF and serum of symptomatic patients with probable or definite CNS NS (01/2011–02/2023) with gadolinium enhancement and/or CSF pleocytosis. Patients with multiple sclerosis, primary CNS lymphoma, aquaporin‐4 immunoglobulin G positivity, non‐inflammatory disorders, and healthy individuals were used as controls.ResultsA total of 32 NS patients (59% women; median age, 59 years [19–81]) were included; concurrent sera were available in 12. CSF controls consisted of 26 multiple sclerosis, 8 primary CNS lymphoma, 84 aquaporin‐4 immunoglobulin G positive, and 34 patients with non‐inflammatory disorders. Gadolinium enhancement was present in 31 of 32 NS patients, and CSF pleocytosis in 27 of 32 (84%). CSF IL‐2, IL‐6, IL‐10, IL‐13, BAFF, IL‐8/CXCL8, CXCL9, CXCL10, CXCL13, GM‐CSF, interferon‐gamma, and TNF‐alpha levels were significantly higher in NS patients compared with non‐inflammatory controls (p ≤ 0.02); elevations were more common in CSF than serum. Concurrent elevation of IL‐6, CXCL9, CXCL10, GM‐CSF, interferon‐gamma, and TNF‐alpha was present in 18 of 32 NS patients, but only in 1 control. Elevated IL‐6, IL‐10, IL‐13, CXCL9, CXL10, GM‐CSF, and TNF‐alpha associated with measures of disease activity.InterpretationNS CSF cytokine/chemokine profiles suggest T cell (mainly T helper cell type 1), macrophage, and B‐cell involvement. These signatures aid in NS diagnosis, indicate disease activity, and suggest therapeutic avenues. ANN NEUROL 2024;96:704–714